WallStSmart

Boston Scientific Corp (BSX)vsCeriBell, Inc (CBLL)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Boston Scientific Corp generates 22439% more annual revenue ($20.07B vs $89.06M). BSX leads profitability with a 14.4% profit margin vs -60.0%. BSX earns a higher WallStSmart Score of 63/100 (C+).

BSX

Buy

63

out of 100

Grade: C+

Growth: 8.0Profit: 6.5Value: 8.7Quality: 5.5
Piotroski: 4/9

CBLL

Avoid

33

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BSXUndervalued (+1.2%)

Margin of Safety

+1.2%

Fair Value

$70.62

Current Price

$69.78

$0.84 discount

UndervaluedFair: $70.62Overvalued

Intrinsic value data unavailable for CBLL.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BSX4 strengths · Avg: 8.3/10
Market CapQuality
$101.28B9/10

Large-cap with strong market position

PEG RatioValuation
0.758/10

Growing faster than its price suggests

Revenue GrowthGrowth
15.9%8/10

15.9% revenue growth

Free Cash FlowQuality
$1.01B8/10

Generating 1.0B in free cash flow

CBLL1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
33.7%10/10

Revenue surging 33.7% year-over-year

Areas to Watch

BSX1 concerns · Avg: 4.0/10
P/E RatioValuation
35.1x4/10

Premium valuation, high expectations priced in

CBLL4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$696.36M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-30.8%2/10

ROE of -30.8% — below average capital efficiency

Free Cash FlowQuality
$-10.95M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : BSX

The strongest argument for BSX centers on Market Cap, PEG Ratio, Revenue Growth. Revenue growth of 15.9% demonstrates continued momentum. PEG of 0.75 suggests the stock is reasonably priced for its growth.

Bull Case : CBLL

The strongest argument for CBLL centers on Revenue Growth. Revenue growth of 33.7% demonstrates continued momentum.

Bear Case : BSX

The primary concerns for BSX are P/E Ratio.

Bear Case : CBLL

The primary concerns for CBLL are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

BSX profiles as a growth stock while CBLL is a hypergrowth play — different risk/reward profiles.

CBLL is growing revenue faster at 33.7% — sustainability is the question.

BSX generates stronger free cash flow (1.0B), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

BSX scores higher overall (63/100 vs 33/100) and 15.9% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

CeriBell, Inc

HEALTHCARE · MEDICAL DEVICES · USA

CeriBell, Inc. develops AI based point-of-care electroencephalography (EEG) technology for the detection and treatment of neurological conditions. The company is headquartered in Sunnyvale, California.

Want to dig deeper into these stocks?